A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH

NCT03970031 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

1800

Enrollment

INDUSTRY

Sponsor class

Conditions

Type2 Diabetes
NASH - Nonalcoholic Steatohepatitis
Nonalcoholic Steatohepatitis
Non-Alcoholic Fatty Liver Disease

Interventions

DRUG: MSDC-0602K
DRUG: Placebo

Sponsor

Cirius Therapeutics, Inc.